A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome
He H, Zhao D, Jiang H, et al.
Am J Hematol · 2018
Grade Bcohortn=41
Key Findings
- ●Complete hematologic response 46%, neurologic response 95%
- ●VEGF response 83%, median time to response 2 months
- ●3-year OS 90%, 3-year PFS 75%
- ●No treatment-related deaths or grade 3+ lenalidomide adverse events
Referenced in (1 disease)
ID: pmid-29603764DOI: 10.1002/ajh.25108PMID: 29603764